Loading...
UNBX logo

Unity Biotechnology, Inc.OTCPK:UNBX Stock Report

Market Cap US$965.6k
Share Price
n/a
1Y-96.2%
7D-6.5%
1D0.4%
Portfolio Value
​
View

Unity Biotechnology, Inc.

OTCPK:UNBX Stock Report

Market Cap: US$965.6k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Unity Biotechnology (UNBX) Stock Overview

A biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. More details

UNBX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Earnings have grown 27.6% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Negative shareholders equity

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($966K)


UNBX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW427,399 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
427,399 investors already sharing narratives
View all narratives

Unity Biotechnology, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Unity Biotechnology
Historical stock prices
Current Share PriceUS$0.056
52 Week HighUS$3.10
52 Week LowUS$0.049
Beta1.19
1 Month Change-12.34%
3 Month Change-80.85%
1 Year Change-96.16%
3 Year Change-98.55%
5 Year Change-99.85%
Change since IPO-99.97%

Recent News & Updates

Recent updates

Analysis Article • Nov 05

Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jul 12

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 05

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Nov 18

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 19

UNITY Biotechnology falls 7% on reverse stock split

Unity Biotechnology (NASDAQ:UBX) announced on Wednesday a 1-for-10 reverse stock split of its common stock, sending its shares down 7.6% in premarket trading. The reverse stock split will become effective at 5:00 PM on Wednesday. The company said it was going ahead with the reverse stock split to be in compliance with the minimum required closing bid price for continued listing on the Nasdaq Global Select Market. The reverse stock split was approved by UNITY’s stockholders at a special meeting of stockholders held on October 18.
Seeking Alpha • Aug 19

Unity Biotechnology cuts stock sales agreement in half to $25M

Unity Biotechnology (NASDAQ:UBX) has halved a stock sales agreement to $25M from $50M, according to a Friday SEC filing. The sales agreement is through Cowen. Unity noted that it already sold $8.9M worth of shares under the agreement. On Thursday, the company priced shares of another offering of its common stock and accompanying warrants at a combined public offering price of $0.70/share and accompanying warrant. The gross proceeds are expected to be $45M.
Seeking Alpha • Aug 12

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Unity Biotechnology press release (NASDAQ:UBX): Q2 GAAP EPS of -$0.19 beats by $0.10. Revenue of $0.24M. Cash, cash equivalents and marketable securities totaled $64.5 million as of June 30, 2022, compared with $79.2 million as of March 31, 2022.  UNITY believes that current cash, cash equivalents, and marketable securities are sufficient to fund operations through the first quarter of 2023. Shares +96% PM.
Seeking Alpha • Jul 26

A Look At Unity's UBX1325 Phase 1 Results

I recently covered Unity's transition away from its failed osteoarthritis program to its ophthalmology program focused on retinal diseases. UBX1325 had posted strong preclinical results that suggested senescent cells might actually be causally involved in various retinal disease pathologies. Unity recently posted results from its first-in-human Phase 1 trial of UBX1325 that I thought merited a closer look.
Analysis Article • Dec 22

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Some Unity Biotechnology, Inc. ( NASDAQ:UBX ) shareholders may be a little concerned to see that the Co-Founder...

Shareholder Returns

UNBXUS BiotechsUS Market
7D-6.5%0.4%-0.2%
1Y-96.2%36.4%11.9%

Return vs Industry: UNBX underperformed the US Biotechs industry which returned -1.6% over the past year.

Return vs Market: UNBX underperformed the US Market which returned 18.1% over the past year.

Price Volatility

Is UNBX's price volatile compared to industry and market?
UNBX volatility
UNBX Average Weekly Movement37.1%
Biotechs Industry Average Movement9.5%
Market Average Movement6.8%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.9%

Stable Share Price: UNBX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: UNBX's weekly volatility has increased from 24% to 37% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200916n/aunitybiotechnology.com

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications.

Unity Biotechnology, Inc. Fundamentals Summary

How do Unity Biotechnology's earnings and revenue compare to its market cap?
UNBX fundamental statistics
Market capUS$965.60k
Earnings (TTM)-US$27.50m
Revenue (TTM)n/a
0.0x
P/S Ratio
0.0x
P/E Ratio

Is UNBX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UNBX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$12.06m
Gross Profit-US$12.06m
Other ExpensesUS$15.45m
Earnings-US$27.50m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.60
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did UNBX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 07:20
End of Day Share Price 2025/10/01 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Unity Biotechnology, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yigal NochomovitzCitigroup Inc
Matthew HarrisonMorgan Stanley
Dylan DupuisRoth Capital Partners